STOK Nov 2024 7.500 call
| Previous close | 1.3000 |
| Open | 1.3000 |
| Bid | 4.8000 |
| Ask | 8.0000 |
| Strike | 7.50 |
| Expiry date | 2024-11-15 |
| Day's range | 1.3000 - 1.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GuruFocus.comInsider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares
On May 20, 2024, Edward M. Kaye, MD, Chief Executive Officer of Stoke Therapeutics Inc (NASDAQ:STOK), executed a significant stock transaction, selling 42,350 shares of the company.
Business WireStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass., May 17, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on May 15, 2024, the company granted stock options of common stock to Thomas Leggett, the Company’s newly-appointed Chief Financial Officer, and four other new employees as a material inducement to their employment in accordance with Nasdaq Listing
GuruFocus.comStoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ...
Despite Narrow Miss on EPS, Stoke Therapeutics Advances in Clinical Developments
